EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Dopamine and prolactin in migraine: Mechanisms and potential therapeutic targets

Astrid Johannesson Hjelholt iD, Randi Maria Hanghøj Tei, Hans Christoph Diener, Jens Otto Lunde Jørgensen

Journal of Neuroendocrinology · 2025-12 · 37 (12)

DOI: 10.1111/jne.70098 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neuroendocrinology, online erschienen am 06.10.2025. Verfasst von Astrid Johannesson Hjelholt und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Prolactin, Migraine Disorders, Dopamine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Migraine is a complex neurovascular disorder characterized by activation and sensitization of the trigeminovascular system. Hyperprolactinemia is associated with headache, and improvement following prolactin‐lowering therapy has been reported in observational studies. Preclinical evidence indicates that prolactin promotes neuronal excitability and sensitization within trigeminal pathways, particularly in females. Downregulation of the protective long prolactin receptor isoform further increases susceptibility to migraine‐relevant triggers. Prolactin secretion is under tonic inhibition by dopamine, a key hypothalamic regulator that also modulates central pain pathways. The role of dopamine in migraine pathophysiology is complex. On one hand, prodromal symptoms such as nausea and yawning are considered dopamine‐mediated. On the other hand, experimental studies show that dopamine directly inhibits nociceptive trigeminovascular activity in addition to lowering prolactin. Dopamine receptor agonists are established treatments for hyperprolactinemia and have demonstrated a positive effect on hyperprolactinemia‐associated headache. A recent placebo‐controlled randomized clinical trial suggests that dopamine agonist treatment can be used as a preventive migraine treatment. In conclusion, prolactin and dopamine may modulate migraine via distinct but converging neuroendocrine pathways, which could represent targets for migraine prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProlactinMigraine DisordersDopamineHumansAnimalsHyperprolactinemiaDopamine Agonists

Stichwörter der Autor:innen

dopaminedopamine receptor agonistsmigraineprolactin

Substanzen

ProlactinDopamineDopamine Agonists

Autor:innen und Institutionen

  • Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Neuroepidemiology, Institute for Medical Informatics, Biometry and Epidemiology, Faculty of Medicine, University Duisburg-Essen, Essen, Germany.

ORCID-Profile: Astrid Johannesson Hjelholt

Zitieren

APA

Hjelholt, A. J., Tei, R. M. H., Diener, H. C., & Jørgensen, J. O. L. (2025). Dopamine and prolactin in migraine: Mechanisms and potential therapeutic targets. Journal of Neuroendocrinology, 37(12). https://doi.org/10.1111/jne.70098

Vancouver

Hjelholt AJ, Tei RMH, Diener HC, Jørgensen JOL. Dopamine and prolactin in migraine: Mechanisms and potential therapeutic targets. Journal of Neuroendocrinology. 2025;37(12). doi:10.1111/jne.70098

BibTeX
@article{Hjelholt2025,
  author = {Hjelholt, Astrid Johannesson and Tei, Randi Maria Hanghøj and Diener, Hans Christoph and Jørgensen, Jens Otto Lunde},
  title = {Dopamine and prolactin in migraine: Mechanisms and potential therapeutic targets},
  journal = {Journal of Neuroendocrinology},
  year = {2025},
  volume = {37},
  number = {12},
  doi = {10.1111/jne.70098}
}
Kostenlos starten →